Physician profile
Bill B Lawrence
NPI 1154344810
$3,360.85
in general payments reported to CMS, 2019-2025
42 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $319 · 2021: $518 · 2022: $454 · 2023: $492 · 2024: $472 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $377.49 | 2019-2025 | |
| Novo Nordisk INC | $371.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $255.24 | 2019-2025 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $235.33 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $214.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $178.52 | 2019-2022 | |
| Abbott Laboratories | $155.82 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Abbvie INC. | $130.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $128.33 | 2019-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.50 | 2020-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $89.80 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $89.03 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $83.71 | 2022-2025 | |
| Shire North American Group INC | $82.86 | 2019 | |
| Glaxosmithkline, LLC. | $81.18 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.